Compare Heron Therapeutics Inc (HRTX) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $61.47M), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $122.94. The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | QQQE | |
|---|---|---|
Market Cap | $61.47M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.49 | $122.72 |
52-Week Low | $0.32 | $96.06 |
Enterprise Value | $168.21M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
QQQE, the Direxion NASDAQ-100 Equal Weighted Index ETF, trades at $123.01, up 0.7% today, with a bullish technical signal from moving averages. The fund provides diversified exposure to the Nasdaq-100 with equal weighting, reducing concentration risk compared to cap-weighted peers. Recent news highlights its appeal as a defensive play amid tech-led market rallies and the upcoming inclusion of SpaceX in the index.
The outlook remains positive given equal-weight diversification benefits and strong Nasdaq-100 growth trends. Key risks include market volatility and sector concentration, but analyst sentiment favors QQQE for balanced Nasdaq exposure. The ETF's structure mitigates single-stock risk while capturing broad large-cap growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
